II. in vitro evidence that (2)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors

Journal of Neural Transmission

Volumn 118, Issue 11, 2011, Pages 1523-1533

  Burstein, Ethan S ^a   Carlsson, Maria L ^b   Owens, Michelle ^a,c   Ma, Jian Nong ^a   Schiffer, Hans H ^a,d   Carlsson, Arvid ^b   Hacksell, Uli ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c DART NEUROSCIENCE LLC   (United States)

^d Envoy Therapeutics   (United States)

Author keywords

Agonist; Allosteric; Dopamine receptor; Dopamine stabilizer; G protein coupled receptor; Monoamine; Orthosteric; Partial agonist; Serotonin receptor

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; BETA ARRESTIN; DOPAMINE 2 RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PHOSPHATIDYLINOSITOL; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIORAL EFFECT; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID HYDROLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL MEMBRANE; DOPAMINE AGONISTS; HEK293 CELLS; HUMANS; MICE; NIH 3T3 CELLS; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SUBCELLULAR FRACTIONS;

EID: 84855232671     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0701-y     Document Type: Article

References (22)

1. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315:1278-1287 (Pubitemid 41635416)
2. Burstein ES, Piu F, Ma JN, Weissman JT, Currier EA, Nash NR, Weiner DM, Spalding TA, Schiffer HH, Del Tredici AL, Brann MR (2006a) Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout. Curr Pharm Des 12:1717-1729
3. Burstein ES, Ott TR, Feddock M, Ma JN, Fuhs S, Wong S, Schiffer HH, Brann MR, Nash NR (2006b) Characterization of the Masrelated gene family: structural and functional conservation of human and rhesus MrgX receptors. Br J Pharmacol 147:73-82 (Pubitemid 43069098)
4. Carlsson ML, Burstein ES, Kloberg A, Hansson S, Schedwin A, Nilsson M, Rung JP, Carlsson A. In vivo evidence for partial agonist effects of -(-)-OSU6162 and (?)-OSU6162 on 5-HT2A serotonin receptors. Submitted as accompanying paper.
5. Filipová M, Filip V, Macek Z, Müllerová S, Marková J, Kás S, Zizková B, Krivka J, Votavová M, Krejcová H (1988) Terguride in parkinsonism. A multicenter trial. Eur Arch Psychiatry Neurol Sci 237:298-303
6. Gardell LR, Ma JN, Seitzberg JG, Knapp AE, Schiffer HH, Tabatabaei A, Davis CN, Owens M, Clemons B, Wong KK, Lund B, Nash NR, Gao Y, Lameh J, Schmelzer K, Olsson R, Burstein ES (2008) Identification and characterization of novel small-molecule protease-activated receptor 2 agonists. J Pharmacol Exp Ther 327:799-808
7. Kara E, Lin H, Svensson K, Johansson AM, Strange PG (2010) Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol 161:1343-1350
8. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 43:2-11 (Pubitemid 28059067)
9. Lahti RA, Tamminga CA, Carlsson A (2007) Stimulating and inhibitory effects of the dopamine ''stabilizer'' (-)-OSU-6162 on dopamine D(2) receptor function in vitro. J Neural Transm 114:1143-1146 (Pubitemid 47313178)
10. Ma JN, Schiffer HH, Knapp AE, Wang J, Wong KK, Currier EA, Owens M, Nash NR, Gardell LR, Brann MR, Olsson R, Burstein ES (2007) Identification of the atypical L-type Ca2? Channel blocker diltiazem and its metabolites as ghrelin receptor agonists. Mol Pharmacol 72:380-386 (Pubitemid 47124118)
11. Ma JN, Owens M, Gustafsson M, Jensen J, Tabatabaei A, Schmelzer K, Olsson R, Burstein ES (2011) Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor. J Pharmacol Exp Ther 337:275-284
12. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, Caron MG (2008) Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105:13656-13661
13. Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, Kapur S (2006) The dopamine stabilizers (S)- (-)-(3-methanesulfonyl-phenyl)-1- propyl-piperidine [(-)-OSU- 6162] and 4-(3-methanesulfonylphenyl)-1-propyl- piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic- like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318:810-818 (Pubitemid 44061255)
14. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (2010) Partial agonists in schizophrenia-why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol 19:1-14
15. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III.Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303:815-822 (Pubitemid 35231258)
16. Olbrich R, Schanz H (1991) An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J Neural Transm Gen Sect 84:233-236
17. Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A, Carlsson ML (2008) Effects of (-)-OSU-6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm 115:899-908
18. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411 (Pubitemid 41070874)
19. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR (2002) Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol 61:1297-1302 (Pubitemid 34575739)
20. Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A (1999) Longlasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurology 53:1605-1606 (Pubitemid 29491967)
21. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR (2001) 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299:268-276 (Pubitemid 32905144)
22. Weissman JT, Ma JN, Essex A, Gao Y, Burstein ES (2004) G-proteincoupled receptor-mediated activation of rap GTPases: characterization of a novel Galphai regulated pathway. Oncogene 23:241-249 (Pubitemid 38142258)